Table 1 The ARID1A immunoreactivity in the putative precursor lesions of ovarian clear-cell carcinomas
Number of cases (%) | ||
|---|---|---|
ARID1A | ARID1A | |
Type of precursor lesion | Deficient | Intact |
In the endometriosis-associated carcinomas | ||
In the ARID1A-deficient carcinomas | ||
Non-atypical endometriosis (distant; n=10) | 0 | 10 (100) |
Non-atypical endometriosis (adjacent; n=14) | 12 (86)a | 2 (14) |
Atypical endometriosis (adjacent; n=14) | 14 (100) | 0 |
In the ARID1A-intact carcinomas | ||
Non-atypical endometriosis (adjacent; n=7) | 0 | 7 (100) |
Atypical endometriosis (n=8) | 0 | 8 (100) |
In the adenofibroma-associated carcinomas | ||
In the ARID1A-deficient carcinomas | ||
Benign clear-cell adenofibroma (adjacent; n=3) | 3 (100) | 0 |
Borderline clear-cell adenofibroma (adjacent; n=6) | 6 (100) | 0 |
In the ARID1A-intact carcinomas | ||
Benign clear-cell adenofibroma (adjacent; n=10) | 0 | 7 (100) |
Borderline clear-cell adenofibroma (adjacent; n=14) | 0 | 7 (100) |
